{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:38:35Z","timestamp":1780583915877,"version":"3.54.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Saskatchewan Cancer Agency","award":["1-417521"],"award-info":[{"award-number":["1-417521"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81372443"],"award-info":[{"award-number":["81372443"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100008868","name":"Science and Technology Department of Jiangsu Province","doi-asserted-by":"crossref","award":["BY2015039-03"],"award-info":[{"award-number":["BY2015039-03"]}],"id":[{"id":"10.13039\/501100008868","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Health and Family Planning Commission of Jiangsu Province","award":["LGY2016030"],"award-info":[{"award-number":["LGY2016030"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.vaccine.2018.01.078","type":"journal-article","created":{"date-parts":[[2018,2,4]],"date-time":"2018-02-04T23:33:56Z","timestamp":1517787236000},"page":"1414-1422","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Heterologous human\/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2\/HER2 mice"],"prefix":"10.1016","volume":"36","author":[{"given":"Yufeng","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aizhang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahid","family":"Ahmeqd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer","family":"Sami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajni","family":"Chibbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Freywald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.01.078_b0005","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2018.01.078_b0010","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1126\/science.2992090","article-title":"The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor","volume":"229","author":"Schechter","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2018.01.078_b0015","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1158\/0008-5472.CAN-09-2548","article-title":"A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat\/human chimeric proteins","volume":"70","author":"Quaglino","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2018.01.078_b0020","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","article-title":"Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer","volume":"20","author":"Vogel","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.vaccine.2018.01.078_b0025","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","article-title":"A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer","volume":"12","author":"Berns","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.vaccine.2018.01.078_b0030","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.canlet.2005.01.041","article-title":"Herceptin: mechanisms of action and resistance","volume":"232","author":"Nahta","year":"2006","journal-title":"Cancer Lett"},{"key":"10.1016\/j.vaccine.2018.01.078_b0035","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1158\/1078-0432.CCR-07-0701","article-title":"Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network","volume":"13","author":"Ritter","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2018.01.078_b0040","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s10549-007-9885-0","article-title":"A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses","volume":"112","author":"Cameron","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.vaccine.2018.01.078_b0045","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.1999.17.9.2639","article-title":"Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease","volume":"17","author":"Cobleigh","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.vaccine.2018.01.078_b0050","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/sj.bjc.6603060","article-title":"Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study","volume":"94","author":"Bengala","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.vaccine.2018.01.078_b0055","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/bcr1612","article-title":"HER2 therapy: molecular mechanisms of trastuzumab resistance","volume":"8","author":"Nahta","year":"2006","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.vaccine.2018.01.078_b0060","first-page":"277","article-title":"Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation","volume":"4","author":"Ye","year":"2007","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.vaccine.2018.01.078_b0065","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nri2785","article-title":"FOXP3+ regulatory T cells in the human immune system","volume":"10","author":"Sakaguchi","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2018.01.078_b0070","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.immuni.2009.05.002","article-title":"Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor?","volume":"30","author":"Curotto de Lafaille","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2018.01.078_b0075","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nm1363","article-title":"Autoimmunity and tumor immunity induced by immune responses to mutations in self","volume":"12","author":"Engelhorn","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2018.01.078_b0080","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1600-065X.1995.tb00071.x","article-title":"Evolution of the T-cell repertoire during the course of experimental immune-mediated demyelinating diseases","volume":"144","author":"Miller","year":"1995","journal-title":"Immunol Rev"},{"key":"10.1016\/j.vaccine.2018.01.078_b0085","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0024-3205(97)00480-3","article-title":"Collagen-induced arthritis, an animal model of autoimmunity","volume":"61","author":"Myers","year":"1997","journal-title":"Life Sci"},{"key":"10.1016\/j.vaccine.2018.01.078_b0090","doi-asserted-by":"crossref","first-page":"7626","DOI":"10.4049\/jimmunol.177.11.7626","article-title":"Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB\/c mice","volume":"177","author":"Rolla","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.01.078_b0095","doi-asserted-by":"crossref","first-page":"7734","DOI":"10.1158\/0008-5472.CAN-06-1432","article-title":"Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance","volume":"66","author":"Ambrosino","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2018.01.078_b0100","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1158\/0008-5472.CAN-09-2554","article-title":"Combining human and rat sequences in her-2 DNA vaccines blunts immune tolerance and drives antitumor immunity","volume":"70","author":"Jacob","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2018.01.078_b0105","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/sj.gt.3302797","article-title":"HER-2\/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2\/neu-specific immune responses compared to DNA vaccination","volume":"13","author":"Chan","year":"2006","journal-title":"Gene Ther"},{"key":"10.1016\/j.vaccine.2018.01.078_b0110","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.4049\/jimmunol.179.5.2731","article-title":"Novel exosome-targeted CD4+ T cell vaccine counteracting CD4+25+ regulatory T cell-mediated immune suppression and stimulating efficient central memory CD8+ CTL responses","volume":"179","author":"Hao","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.01.078_b0115","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1189\/jlb.0407249","article-title":"Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory","volume":"82","author":"Hao","year":"2007","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.vaccine.2018.01.078_b0120","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10549-013-2626-7","article-title":"Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2\/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice","volume":"140","author":"Wang","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.vaccine.2018.01.078_b0125","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/cgt.2011.18","article-title":"Adjuvant effect of HER-2\/neu-specific adenoviral vector stimulating CD8(+) T and natural killer cell responses on anti-HER-2\/neu antibody therapy for well-established breast tumors in HER-2\/neu transgenic mice","volume":"18","author":"Chen","year":"2011","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.vaccine.2018.01.078_b0130","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/cgt.2008.18","article-title":"Vaccination of fiber-modified adenovirus-transfected dendritic cells to express HER-2\/neu stimulates efficient HER-2\/neu-specific humoral and CTL responses and reduces breast carcinogenesis in transgenic mice","volume":"15","author":"Sas","year":"2008","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.vaccine.2018.01.078_b0135","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/sj.cgt.7700498","article-title":"Enhanced HER-2\/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2\/neu and alpha tumor necrosis factor","volume":"9","author":"Chen","year":"2002","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.vaccine.2018.01.078_b0140","doi-asserted-by":"crossref","first-page":"9018","DOI":"10.1158\/0008-5472.CAN-07-1691","article-title":"Trastuzumab-resistant HER2-driven breast cancer cells are sensitive to epigallocatechin-3 gallate","volume":"67","author":"Eddy","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2018.01.078_b0145","doi-asserted-by":"crossref","first-page":"5787","DOI":"10.4049\/jimmunol.171.11.5787","article-title":"Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines","volume":"171","author":"Piechocki","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.01.078_b0150","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1016\/j.vaccine.2011.02.095","article-title":"GP120-specific exosome-targeted T cell-based vaccine capable of stimulating DC- and CD4(+) T-independent CTL responses","volume":"29","author":"Nanjundappa","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.078_b0155","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0022-1759(01)00487-2","article-title":"Quantitative measurement of anti-ErbB-2 antibody by flow cytometry and ELISA","volume":"259","author":"Piechocki","year":"2002","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2018.01.078_b0160","first-page":"371","article-title":"Intratumoral vaccination of adenoviruses expressing fusion protein RM4\/tumor necrosis factor (TNF)-alpha induces significant tumor regression","volume":"5","author":"Wright","year":"1998","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.vaccine.2018.01.078_b0165","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1535-6108(04)00083-2","article-title":"Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex","volume":"5","author":"Franklin","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.vaccine.2018.01.078_b0170","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature01392","article-title":"Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab","volume":"421","author":"Cho","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2018.01.078_b0175","doi-asserted-by":"crossref","first-page":"7502","DOI":"10.1158\/0008-5472.CAN-08-1489","article-title":"DNA vaccination controls Her-2+ tumors that are refractory to targeted therapies","volume":"68","author":"Whittington","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2018.01.078_b0180","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1158\/0008-5472.CAN-08-3092","article-title":"Genetic regulation of the response to Her-2 DNA vaccination in human Her-2 transgenic mice","volume":"69","author":"Radkevich-Brown","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2018.01.078_b0185","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1002\/cncr.26574","article-title":"Clinical trial results of the HER-2\/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02","volume":"118","author":"Mittendorf","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.vaccine.2018.01.078_b0190","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nature01441","article-title":"CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes","volume":"421","author":"Janssen","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2018.01.078_b0195","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1158\/0008-5472.CAN-12-1127","article-title":"Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination","volume":"73","author":"Aarntzen","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2018.01.078_b0200","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1172\/JCI11752","article-title":"Immunization with a HER-2\/neu helper peptide vaccine generates HER-2\/neu CD8 T-cell immunity in cancer patients","volume":"107","author":"Knutson","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2018.01.078_b0205","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fimmu.2014.00174","article-title":"How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?","volume":"5","author":"Haabeth","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2018.01.078_b0210","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3389\/fimmu.2017.00194","article-title":"CD4 CTL, a cytotoxic subset of CD4+ T cells, their differentiation and function","volume":"8","author":"Takeuchi","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2018.01.078_b0215","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1056\/NEJMoa0800251","article-title":"Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1","volume":"358","author":"Hunder","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2018.01.078_b0220","doi-asserted-by":"crossref","first-page":"5346","DOI":"10.1182\/blood-2006-10-051318","article-title":"CD4 cells can be more efficient at tumor rejection than CD8 cells","volume":"109","author":"Perez-Diez","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2018.01.078_b0225","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1002\/eji.1830191209","article-title":"Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells","volume":"19","author":"Panina-Bordignon","year":"1989","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2018.01.078_b0230","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.4049\/jimmunol.171.3.1588","article-title":"HER-2 DNA and protein vaccines containing potent Th cell epitopes induce distinct protective and therapeutic antitumor responses in HER-2 transgenic mice","volume":"171","author":"Renard","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.01.078_b0235","doi-asserted-by":"crossref","first-page":"329","DOI":"10.4049\/jimmunol.175.1.329","article-title":"Linked foreign T-cell help activates self-reactive CTL and inhibits tumor growth","volume":"175","author":"Steinaa","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.01.078_b0240","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/0264-410X(94)90337-9","article-title":"Immunogenicity of an alum-adsorbed synthetic multiple-antigen peptide based on B- and T-cell epitopes of the Plasmodium falciparum CS protein: possible vaccine application","volume":"12","author":"de Oliveira","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.078_b0245","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/cgt.2013.60","article-title":"Potent CD4+ T-cell epitope P30 enhances HER2\/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses","volume":"20","author":"Xie","year":"2013","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.vaccine.2018.01.078_b0250","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00262-005-0692-3","article-title":"Immunogenic HER-2\/neu peptides as tumor vaccines","volume":"55","author":"Baxevanis","year":"2006","journal-title":"Cancer Immunol Immunother"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18301518?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18301518?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:27:30Z","timestamp":1759400850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18301518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0264410X18301518"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.01.078","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heterologous human\/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2\/HER2 mice","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.01.078","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}